Eltrombopag Suppliers & Bulk Manufacturers
Available Forms: Tablets & Oral suspension
Available Strengths: Tablet: 25 mg, 50 mg, 75 mg; Suspension: 12.5 mg/5 mL
Reference Brands: Promacta® (US & EU); Revolade®(EU)
Category:
Hepatitis
Eltrombopag Tablets (Promacta® / Revolade® generic) are oral TPO receptor agonists for ITP, aplastic anemia, and HCV-related thrombocytopenia. Available in 25 mg, 50 mg, and 75 mg strengths. EU-GMP/USFDA compliant, ideal for B2B supply, tenders, and licensing with full CTD support.
Eltrombopag is available in Tablets & Oral suspension
and strengths such as Tablet: 25 mg, 50 mg, 75 mg; Suspension: 12.5 mg/5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Eltrombopag is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Eltrombopag can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Eltrombopag Tablets (Promacta® / Revolade® generic) are thrombopoietin receptor agonists indicated for chronic ITP, severe aplastic anemia, and HCV-related thrombocytopenia. Available in 25 mg, 50 mg, and 75 mg oral tablet strengths, the product is manufactured under EU-GMP and USFDA-compliant facilities. Offered for B2B supply, hospital tenders, and licensing deals, with full CTD dossiers, bioequivalence studies, and regulatory support. Eltrombopag is a key addition for companies supplying hematology and oncology portfolios in regulated and semi-regulated markets, supporting global access to thrombopoiesis-stimulating therapies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing